Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 257 entries
Sorted by: Best Match Show Resources per page
Eosinophilic Pneumonia in a Patient with Ulcerative Colitis.

Radiology case reports

Patel KB, Robbins MM, Simon ML, Amorosa JK.
PMID: 27303487
Radiol Case Rep. 2015 Dec 07;2(4):49. doi: 10.2484/rcr.2007.v2i4.49. eCollection 2007.

We present the case of 16-year-old woman with a 2-month history of ulcerative colitis who presented with cough, fever, dyspnea on exertion, and nasal congestion. Computed tomography of the chest demonstrated peripheral alveolar opacities with relative sparing of the...

Cite
Patel KB, Robbins MM, Simon ML, et al. Eosinophilic Pneumonia in a Patient with Ulcerative Colitis. Radiol Case Rep. 2015;2(4):49doi: 10.2484/rcr.2007.v2i4.49.
Patel, K. B., Robbins, M. M., Simon, M. L., & Amorosa, J. K. (2007). Eosinophilic Pneumonia in a Patient with Ulcerative Colitis. Radiology case reports, 2(4), 49. https://doi.org/10.2484/rcr.2007.v2i4.49
Patel, Keyur B, et al. "Eosinophilic Pneumonia in a Patient with Ulcerative Colitis." Radiology case reports vol. 2,4 (2007): 49. doi: https://doi.org/10.2484/rcr.2007.v2i4.49
Patel KB, Robbins MM, Simon ML, Amorosa JK. Eosinophilic Pneumonia in a Patient with Ulcerative Colitis. Radiol Case Rep. 2015 Dec 07;2(4):49. doi: 10.2484/rcr.2007.v2i4.49. eCollection 2007. PMID: 27303487; PMCID: PMC4896014.
Copy Download .nbib Format: NLM
Hepatopancreatobiliary manifestations of inflammatory bowel disease.

Clinical journal of gastroenterology

Nakamura K, Ito T, Kotoh K, Ihara E, Ogino H, Iwasa T, Tanaka Y, Iboshi Y, Takayanagi R.
PMID: 26181867
Clin J Gastroenterol. 2012 Feb;5(1):1-8. doi: 10.1007/s12328-011-0282-1. Epub 2012 Jan 06.

Inflammatory bowel disease (IBD) is frequently associated with extraintestinal manifestations such as hepatopancreatobiliary manifestations (HPBMs), which include primary sclerosing cholangitis (PSC), pancreatitis, and cholelithiasis. PSC is correlated with IBD, particularly ulcerative colitis (UC); 70-80% of PSC patients in Western...

Cite
Nakamura K, Ito T, Kotoh K, et al. Hepatopancreatobiliary manifestations of inflammatory bowel disease. Clin J Gastroenterol. 2012;5(1):1-8doi: 10.1007/s12328-011-0282-1.
Nakamura, K., Ito, T., Kotoh, K., Ihara, E., Ogino, H., Iwasa, T., Tanaka, Y., Iboshi, Y., & Takayanagi, R. (2012). Hepatopancreatobiliary manifestations of inflammatory bowel disease. Clinical journal of gastroenterology, 5(1), 1-8. https://doi.org/10.1007/s12328-011-0282-1
Nakamura, Kazuhiko, et al. "Hepatopancreatobiliary manifestations of inflammatory bowel disease." Clinical journal of gastroenterology vol. 5,1 (2012): 1-8. doi: https://doi.org/10.1007/s12328-011-0282-1
Nakamura K, Ito T, Kotoh K, Ihara E, Ogino H, Iwasa T, Tanaka Y, Iboshi Y, Takayanagi R. Hepatopancreatobiliary manifestations of inflammatory bowel disease. Clin J Gastroenterol. 2012 Feb;5(1):1-8. doi: 10.1007/s12328-011-0282-1. Epub 2012 Jan 06. PMID: 26181867.
Copy Download .nbib Format: NLM
Treatment and outcomes: medical and surgical treatment for intestinal Behçet's disease.

Intestinal research

Hisamatsu T, Hayashida M.
PMID: 28670228
Intest Res. 2017 Jul;15(3):318-327. doi: 10.5217/ir.2017.15.3.318. Epub 2017 Jun 12.

Behçet's disease (BD) is a chronic relapsing disease involving multiple organ systems. BD is characterized clinically by oral and genital aphthae, cutaneous lesions, and ophthalmological, neurological, and/or gastrointestinal manifestations. It is widely recognized that the presence of intestinal lesions...

Cite
Hisamatsu T, Hayashida M. Treatment and outcomes: medical and surgical treatment for intestinal Behçet's disease. Intest Res. 2017;15(3):318-327doi: 10.5217/ir.2017.15.3.318.
Hisamatsu, T., & Hayashida, M. (2017). Treatment and outcomes: medical and surgical treatment for intestinal Behçet's disease. Intestinal research, 15(3), 318-327. https://doi.org/10.5217/ir.2017.15.3.318
Hisamatsu, Tadakazu, and Hayashida, Mari. "Treatment and outcomes: medical and surgical treatment for intestinal Behçet's disease." Intestinal research vol. 15,3 (2017): 318-327. doi: https://doi.org/10.5217/ir.2017.15.3.318
Hisamatsu T, Hayashida M. Treatment and outcomes: medical and surgical treatment for intestinal Behçet's disease. Intest Res. 2017 Jul;15(3):318-327. doi: 10.5217/ir.2017.15.3.318. Epub 2017 Jun 12. PMID: 28670228; PMCID: PMC5478756.
Copy Download .nbib Format: NLM
[Possibilities of influencing the drug content and encapsulation efficiency of chitosan microspheres prepared by ionic gelation process].

Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti

Kouřil J, Vysloužil J, Kejdušová M, Dvořáčková K, Vetchý D.
PMID: 24870552
Ceska Slov Farm. 2014 Apr;63(2):75-83.

UNLABELLED: This study aimed to prepare high molecular weight chitosan blank and drug-loaded microparticles using 5-aminosalicylic acid (5-ASA) as the model active substance by an external ionic gelation. Formulation and process variables included the chitosan concentration and presence of...

Cite
Kouřil J, Vysloužil J, Kejdušová M, et al. Možnosti ovlivnění obsahu léčiva a enkapsulační účinnosti chitosanových mikrosfér připravených procesem iontové gelace. [Possibilities of influencing the drug content and encapsulation efficiency of chitosan microspheres prepared by ionic gelation process]. Ceska Slov Farm. 2014;63(2):75-83
Kouřil, J., Vysloužil, J., Kejdušová, M., Dvořáčková, K., & Vetchý, D. (2014). Možnosti ovlivnění obsahu léčiva a enkapsulační účinnosti chitosanových mikrosfér připravených procesem iontové gelace. [Possibilities of influencing the drug content and encapsulation efficiency of chitosan microspheres prepared by ionic gelation process]. Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti, 63(2), 75-83.
Kouřil, Jan, et al. "Možnosti ovlivnění obsahu léčiva a enkapsulační účinnosti chitosanových mikrosfér připravených procesem iontové gelace." [Possibilities of influencing the drug content and encapsulation efficiency of chitosan microspheres prepared by ionic gelation process]. Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti vol. 63,2 (2014): 75-83.
Kouřil J, Vysloužil J, Kejdušová M, Dvořáčková K, Vetchý D. Možnosti ovlivnění obsahu léčiva a enkapsulační účinnosti chitosanových mikrosfér připravených procesem iontové gelace. [Possibilities of influencing the drug content and encapsulation efficiency of chitosan microspheres prepared by ionic gelation process]. Ceska Slov Farm. 2014 Apr;63(2):75-83. Czech. PMID: 24870552.
Copy Download .nbib Format: NLM
Matrix effect on in-source decay products of peptides in matrix-assisted laser desorption/ionization.

Mass spectrometry (Tokyo, Japan)

Asakawa D, Sakakura M, Takayama M.
PMID: 24349903
Mass Spectrom (Tokyo). 2012;1(1):A0002. doi: 10.5702/massspectrometry.A0002. Epub 2012 Jul 05.

MALDI-ISD of peptides were studied using several salicylic acid derivatives, 2,5-dihydroxybenzoic acid (2,5-DHB), 5-aminosalicylic acid (5-ASA), 5-formylsalicylic acid (5-FSA), and 5-nitrosalicylic acid (5-NSA) as matrices. The difference in the nature of the functional group at the 5-position in the...

Cite
Asakawa D, Sakakura M, Takayama M. Matrix effect on in-source decay products of peptides in matrix-assisted laser desorption/ionization. Mass Spectrom (Tokyo). 2012;1(1):A0002doi: 10.5702/massspectrometry.A0002.
Asakawa, D., Sakakura, M., & Takayama, M. (2012). Matrix effect on in-source decay products of peptides in matrix-assisted laser desorption/ionization. Mass spectrometry (Tokyo, Japan), 1(1), A0002. https://doi.org/10.5702/massspectrometry.A0002
Asakawa, Daiki, et al. "Matrix effect on in-source decay products of peptides in matrix-assisted laser desorption/ionization." Mass spectrometry (Tokyo, Japan) vol. 1,1 (2012): A0002. doi: https://doi.org/10.5702/massspectrometry.A0002
Asakawa D, Sakakura M, Takayama M. Matrix effect on in-source decay products of peptides in matrix-assisted laser desorption/ionization. Mass Spectrom (Tokyo). 2012;1(1):A0002. doi: 10.5702/massspectrometry.A0002. Epub 2012 Jul 05. PMID: 24349903; PMCID: PMC3775833.
Copy Download .nbib Format: NLM
Peroxisome proliferator-activated receptor-γ is downregulated in ulcerative colitis and is involved in experimental colitis-associated neoplasia.

Oncology letters

Dou X, Xiao J, Jin Z, Zheng P.
PMID: 26622660
Oncol Lett. 2015 Sep;10(3):1259-1266. doi: 10.3892/ol.2015.3397. Epub 2015 Jun 19.

The aim of the present study was to evaluate the expression of peroxisome proliferator-activated receptor (PPAR)-γ in inflammatory bowel disease (IBD), and to also identify the association between PPAR-γ and the clinical features of patients with IBD. An azoxymethane...

Cite
Dou X, Xiao J, Jin Z, et al. Peroxisome proliferator-activated receptor-γ is downregulated in ulcerative colitis and is involved in experimental colitis-associated neoplasia. Oncol Lett. 2015;10(3):1259-1266doi: 10.3892/ol.2015.3397.
Dou, X., Xiao, J., Jin, Z., & Zheng, P. (2015). Peroxisome proliferator-activated receptor-γ is downregulated in ulcerative colitis and is involved in experimental colitis-associated neoplasia. Oncology letters, 10(3), 1259-1266. https://doi.org/10.3892/ol.2015.3397
Dou, Xiaotan, et al. "Peroxisome proliferator-activated receptor-γ is downregulated in ulcerative colitis and is involved in experimental colitis-associated neoplasia." Oncology letters vol. 10,3 (2015): 1259-1266. doi: https://doi.org/10.3892/ol.2015.3397
Dou X, Xiao J, Jin Z, Zheng P. Peroxisome proliferator-activated receptor-γ is downregulated in ulcerative colitis and is involved in experimental colitis-associated neoplasia. Oncol Lett. 2015 Sep;10(3):1259-1266. doi: 10.3892/ol.2015.3397. Epub 2015 Jun 19. PMID: 26622660; PMCID: PMC4533289.
Copy Download .nbib Format: NLM
Usefulness of sulfasalazine for patients with refractory-ulcerative colits.

BMJ open gastroenterology

Yoshino T, Sono M, Yazumi S.
PMID: 27648296
BMJ Open Gastroenterol. 2016 Aug 16;3(1):e000103. doi: 10.1136/bmjgast-2016-000103. eCollection 2016.

BACKGROUND: Patients with refractory-ulcerative colitis (UC) require therapy escalation. Sulfasalazine (SASP) could deliver a high concentration of 5-aminosalicylic acid to the colon. The usefulness of SASP for refractory-UC patients, however, is unclear.AIM: The aim was to evaluate the usefulness...

Cite
Yoshino T, Sono M, Yazumi S. Usefulness of sulfasalazine for patients with refractory-ulcerative colits. BMJ Open Gastroenterol. 2016;3(1):e000103doi: 10.1136/bmjgast-2016-000103.
Yoshino, T., Sono, M., & Yazumi, S. (2016). Usefulness of sulfasalazine for patients with refractory-ulcerative colits. BMJ open gastroenterology, 3(1), e000103. https://doi.org/10.1136/bmjgast-2016-000103
Yoshino, Takuya, et al. "Usefulness of sulfasalazine for patients with refractory-ulcerative colits." BMJ open gastroenterology vol. 3,1 (2016): e000103. doi: https://doi.org/10.1136/bmjgast-2016-000103
Yoshino T, Sono M, Yazumi S. Usefulness of sulfasalazine for patients with refractory-ulcerative colits. BMJ Open Gastroenterol. 2016 Aug 16;3(1):e000103. doi: 10.1136/bmjgast-2016-000103. eCollection 2016. PMID: 27648296; PMCID: PMC5013332.
Copy Download .nbib Format: NLM
Mycobacterial Interspersed Repetitive Unit Can Predict Drug Resistance of Mycobacterium tuberculosis in China.

Frontiers in microbiology

Cheng XF, Jiang C, Zhang M, Xia D, Chu LL, Wen YF, Zhu M, Jiang YG.
PMID: 27047485
Front Microbiol. 2016 Mar 23;7:378. doi: 10.3389/fmicb.2016.00378. eCollection 2016.

BACKGROUND: Recently, Mycobacterial Interspersed Repetitive Unit (MIRU) was supposed to be associated with drug resistance in Mycobacterium tuberculosis (M. tuberculosis), but whether the association exists actually in local strains in China was still unknown. This research was conducted to...

Cite
Cheng XF, Jiang C, Zhang M, et al. Mycobacterial Interspersed Repetitive Unit Can Predict Drug Resistance of Mycobacterium tuberculosis in China. Front Microbiol. 2016;7:378doi: 10.3389/fmicb.2016.00378.
Cheng, X. F., Jiang, C., Zhang, M., Xia, D., Chu, L. L., Wen, Y. F., Zhu, M., & Jiang, Y. G. (2016). Mycobacterial Interspersed Repetitive Unit Can Predict Drug Resistance of Mycobacterium tuberculosis in China. Frontiers in microbiology, 7378. https://doi.org/10.3389/fmicb.2016.00378
Cheng, Xian-Feng, et al. "Mycobacterial Interspersed Repetitive Unit Can Predict Drug Resistance of Mycobacterium tuberculosis in China." Frontiers in microbiology vol. 7 (2016): 378. doi: https://doi.org/10.3389/fmicb.2016.00378
Cheng XF, Jiang C, Zhang M, Xia D, Chu LL, Wen YF, Zhu M, Jiang YG. Mycobacterial Interspersed Repetitive Unit Can Predict Drug Resistance of Mycobacterium tuberculosis in China. Front Microbiol. 2016 Mar 23;7:378. doi: 10.3389/fmicb.2016.00378. eCollection 2016. PMID: 27047485; PMCID: PMC4803746.
Copy Download .nbib Format: NLM
Diversion Colitis.

Current treatment options in gastroenterology

Eggenberger JC, Farid A.
PMID: 11469982
Curr Treat Options Gastroenterol. 2001 Jun;4(3):255-259. doi: 10.1007/s11938-001-0037-z.

Management of the patient with diversion colitis is dependent upon both patient and disease-related factors. Patients in whom diversion is not permanent, who desire stoma closure, and who have an acceptable surgical risk should undergo re-establishment of intestinal continuity....

Cite
Eggenberger JC, Farid A. Diversion Colitis. Curr Treat Options Gastroenterol. 2001;4(3):255-259doi: 10.1007/s11938-001-0037-z.
Eggenberger, J. C., & Farid, A. (2001). Diversion Colitis. Current treatment options in gastroenterology, 4(3), 255-259. https://doi.org/10.1007/s11938-001-0037-z
Eggenberger, John C., and Farid, Asim. "Diversion Colitis." Current treatment options in gastroenterology vol. 4,3 (2001): 255-259. doi: https://doi.org/10.1007/s11938-001-0037-z
Eggenberger JC, Farid A. Diversion Colitis. Curr Treat Options Gastroenterol. 2001 Jun;4(3):255-259. doi: 10.1007/s11938-001-0037-z. PMID: 11469982.
Copy Download .nbib Format: NLM
The history of para-aminosalicylic acid (pas), the first tuberculosis anti-microbial agent, and streptomycin (sm): a comparative study.

Adler Museum bulletin

Dubovsky H.
PMID: 11621575
Adler Mus Bull. 1988 Jun;14(1):7-11.

No abstract available.

Cite
Dubovsky H. The history of para-aminosalicylic acid (pas), the first tuberculosis anti-microbial agent, and streptomycin (sm): a comparative study. Adler Mus Bull. 1988;14(1):7-11
Dubovsky, H. (1988). The history of para-aminosalicylic acid (pas), the first tuberculosis anti-microbial agent, and streptomycin (sm): a comparative study. Adler Museum bulletin, 14(1), 7-11.
Dubovsky, H. "The history of para-aminosalicylic acid (pas), the first tuberculosis anti-microbial agent, and streptomycin (sm): a comparative study." Adler Museum bulletin vol. 14,1 (1988): 7-11.
Dubovsky H. The history of para-aminosalicylic acid (pas), the first tuberculosis anti-microbial agent, and streptomycin (sm): a comparative study. Adler Mus Bull. 1988 Jun;14(1):7-11. PMID: 11621575.
Copy Download .nbib Format: NLM
Arachidonic acid metabolism in TNS-induced chronic and immunologic enteritis in rats, and the effect of 5-ASA.

Mediators of inflammation

Zijlstra FJ, Dijk AP, Selve N, Wilson JH.
PMID: 18475551
Mediators Inflamm. 1993;2(5):391-5. doi: 10.1155/S0962935193000559.

Inflammation of the rat distal intestine was induced by intradermal sensitization and subsequent multiple intrajejunal challenge with the hapten 2,4,6-trinitrobenzenesulphonic acid (TNBS) via an implanted catheter. The time course of the inflammatory reaction was followed by determination of the...

Cite
Zijlstra FJ, Dijk AP, Selve N, et al. Arachidonic acid metabolism in TNS-induced chronic and immunologic enteritis in rats, and the effect of 5-ASA. Mediators Inflamm. 1993;2(5):391-5doi: 10.1155/S0962935193000559.
Zijlstra, F. J., Dijk, A. P., Selve, N., & Wilson, J. H. (1993). Arachidonic acid metabolism in TNS-induced chronic and immunologic enteritis in rats, and the effect of 5-ASA. Mediators of inflammation, 2(5), 391-5. https://doi.org/10.1155/S0962935193000559
Zijlstra, F J, et al. "Arachidonic acid metabolism in TNS-induced chronic and immunologic enteritis in rats, and the effect of 5-ASA." Mediators of inflammation vol. 2,5 (1993): 391-5. doi: https://doi.org/10.1155/S0962935193000559
Zijlstra FJ, Dijk AP, Selve N, Wilson JH. Arachidonic acid metabolism in TNS-induced chronic and immunologic enteritis in rats, and the effect of 5-ASA. Mediators Inflamm. 1993;2(5):391-5. doi: 10.1155/S0962935193000559. PMID: 18475551; PMCID: PMC2365421.
Copy Download .nbib Format: NLM
Comparison of the Kombination therapy of Streptomycin with Sulfone or p-Aminosalicylic acid in experimental Tuberculosis.

Schweizerische medizinische Wochenschrift

MOESCHLIN S, SCHREINER W.
PMID: 18115584
Schweiz Med Wochenschr. 1949 Feb 12;79(6):117.

No abstract available.

Cite
MOESCHLIN S, SCHREINER W. Vergleich der Kombinationstherapie von Streptomycin mit Sulfon oder p-Aminosalicylsāure bei der experimentellen Tuberkulose. Comparison of the Kombination therapy of Streptomycin with Sulfone or p-Aminosalicylic acid in experimental Tuberculosis. Schweiz Med Wochenschr. 1949;79(6):117
MOESCHLIN, S., & SCHREINER, W. (1949). Vergleich der Kombinationstherapie von Streptomycin mit Sulfon oder p-Aminosalicylsāure bei der experimentellen Tuberkulose. Comparison of the Kombination therapy of Streptomycin with Sulfone or p-Aminosalicylic acid in experimental Tuberculosis. Schweizerische medizinische Wochenschrift, 79(6), 117.
MOESCHLIN, S, and SCHREINER, W. "Vergleich der Kombinationstherapie von Streptomycin mit Sulfon oder p-Aminosalicylsāure bei der experimentellen Tuberkulose." Comparison of the Kombination therapy of Streptomycin with Sulfone or p-Aminosalicylic acid in experimental Tuberculosis. Schweizerische medizinische Wochenschrift vol. 79,6 (1949): 117.
MOESCHLIN S, SCHREINER W. Vergleich der Kombinationstherapie von Streptomycin mit Sulfon oder p-Aminosalicylsāure bei der experimentellen Tuberkulose. Comparison of the Kombination therapy of Streptomycin with Sulfone or p-Aminosalicylic acid in experimental Tuberculosis. Schweiz Med Wochenschr. 1949 Feb 12;79(6):117. German. PMID: 18115584.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 257 entries